219 related articles for article (PubMed ID: 16584149)
21. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
22. Dry powder inhalers: physicochemical and aerosolization properties of several size-fractions of a promising alterative carrier, freeze-dried mannitol.
Kaialy W; Nokhodchi A
Eur J Pharm Sci; 2015 Feb; 68():56-67. PubMed ID: 25497318
[TBL] [Abstract][Full Text] [Related]
23. Comminution-amorphisation relationships during ball milling of lactose at different milling conditions.
Pazesh S; Gråsjö J; Berggren J; Alderborn G
Int J Pharm; 2017 Aug; 528(1-2):215-227. PubMed ID: 28546073
[TBL] [Abstract][Full Text] [Related]
24. Aerodynamic Droplet Stream Expansion for the Production of Spray Freeze-Dried Powders.
Wanning S; Süverkrüp R; Lamprecht A
AAPS PharmSciTech; 2017 Jul; 18(5):1760-1769. PubMed ID: 27761706
[TBL] [Abstract][Full Text] [Related]
25. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
Sethuraman VV; Hickey AJ
AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
[TBL] [Abstract][Full Text] [Related]
26. Development of stable influenza vaccine powder formulations: challenges and possibilities.
Amorij JP; Huckriede A; Wilschut J; Frijlink HW; Hinrichs WL
Pharm Res; 2008 Jun; 25(6):1256-73. PubMed ID: 18338241
[TBL] [Abstract][Full Text] [Related]
27. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying.
Seville PC; Kellaway IW; Birchall JC
J Gene Med; 2002; 4(4):428-37. PubMed ID: 12124985
[TBL] [Abstract][Full Text] [Related]
28. Properties of biomass powders resulting from the fine comminution of lignocellulosic feedstocks by three types of ball-mill set-up.
Rajaonarivony RK; Rouau X; Fabre C; Mayer-Laigle C
Open Res Eur; 2021; 1():125. PubMed ID: 37645205
[No Abstract] [Full Text] [Related]
29. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
30. Milling itineraries dataset for a collection of crop and wood by-products and granulometric properties of the resulting powders.
Fabre C; Buche P; Rouau X; Mayer-Laigle C
Data Brief; 2020 Dec; 33():106430. PubMed ID: 33163591
[TBL] [Abstract][Full Text] [Related]
31. The effect of crystal morphology and mill type on milling induced crystal disorder.
Chikhalia V; Forbes RT; Storey RA; Ticehurst M
Eur J Pharm Sci; 2006 Jan; 27(1):19-26. PubMed ID: 16246535
[TBL] [Abstract][Full Text] [Related]
32. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.
Huang J; Garmise RJ; Crowder TM; Mar K; Hwang CR; Hickey AJ; Mikszta JA; Sullivan VJ
Vaccine; 2004 Dec; 23(6):794-801. PubMed ID: 15542204
[TBL] [Abstract][Full Text] [Related]
33. Development and testing of particulate formulations for the nasal delivery of antibodies.
Kaye RS; Purewal TS; Alpar OH
J Control Release; 2009 Apr; 135(2):127-35. PubMed ID: 19059291
[TBL] [Abstract][Full Text] [Related]
34. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
[TBL] [Abstract][Full Text] [Related]
35. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers.
Glover W; Chan HK; Eberl S; Daviskas E; Verschuer J
Int J Pharm; 2008 Feb; 349(1-2):314-22. PubMed ID: 17904774
[TBL] [Abstract][Full Text] [Related]
36. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
37. Spray drying of an attenuated live Newcastle disease vaccine virus intended for respiratory mass vaccination of poultry.
Corbanie EA; Remon JP; Van Reeth K; Landman WJ; van Eck JH; Vervaet C
Vaccine; 2007 Nov; 25(49):8306-17. PubMed ID: 17977632
[TBL] [Abstract][Full Text] [Related]
38. Spray-coating for biopharmaceutical powder formulations: beyond the conventional scale and its application.
Maa YF; Ameri M; Rigney R; Payne LG; Chen D
Pharm Res; 2004 Mar; 21(3):515-23. PubMed ID: 15070104
[TBL] [Abstract][Full Text] [Related]
39. Suitability of differently formulated dry powder Newcastle disease vaccines for mass vaccination of poultry.
Huyge K; Van Reeth K; De Beer T; Landman WJ; van Eck JH; Remon JP; Vervaet C
Eur J Pharm Biopharm; 2012 Apr; 80(3):649-56. PubMed ID: 22155763
[TBL] [Abstract][Full Text] [Related]
40. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation.
Saluja V; Amorij JP; Kapteyn JC; de Boer AH; Frijlink HW; Hinrichs WL
J Control Release; 2010 Jun; 144(2):127-33. PubMed ID: 20219608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
